CVT-301

DRUG6 trials

Sponsors

Acorda Therapeutics

Conditions

Idiopathic Parkinson's DiseaseParkinson's DiseaseSmoking

Phase 1

A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

CompletedNCT02633839

Acorda TherapeuticsSmoking

Start: 2015-12-31End: 2016-06-30Updated: 2016-07-14

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

CompletedNCT03887884

Acorda TherapeuticsParkinson's Disease

Start: 2019-03-05End: 2019-06-28Updated: 2019-08-02

Phase 2

Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and Off Episodes

CompletedNCT01617135

Acorda TherapeuticsIdiopathic Parkinson's Disease

Start: 2012-05-31End: 2012-12-31Updated: 2017-07-27

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

CompletedNCT01777555

Acorda TherapeuticsIdiopathic Parkinson's Disease

Start: 2013-04-30End: 2014-01-31Updated: 2018-08-08

Phase 3

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

CompletedNCT02242487

Acorda TherapeuticsIdiopathic Parkinson's Disease

Start: 2015-03-31End: 2018-05-31Updated: 2019-08-14

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

CompletedNCT02352363

Acorda TherapeuticsIdiopathic Parkinson's Disease

Start: 2015-03-31End: 2017-05-31Updated: 2019-05-28

Related Papers

Natural history of lung function over one year in patients with Parkinson's disease.

2021-04-169 citations

Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease

Clinical Therapeutics2020-05-3019 citations

Effect of Patient Characteristics on Motor Function in Response to 35-50 mg of Inhaled Levodopa (CVT-301) in Patients with Parkinson’s Disease: Results from a Phase 2b Study (P5.372)

Neurology2016-04-05